Allschwil, Switzerland

Thierry Kimmerlin

USPTO Granted Patents = 9 

 

 

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 18(Granted Patents)


Location History:

  • Riehen, CH (2016)
  • Allschwil, CH (2015 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Thierry Kimmerlin: Innovator in Medicinal Chemistry

Introduction

Thierry Kimmerlin is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific enzymes related to cancer treatment. With a total of 9 patents to his name, Kimmerlin's work has the potential to impact therapeutic strategies in oncology.

Latest Patents

Kimmerlin's latest patents include innovative compounds that inhibit indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. These compounds, described in his patent, are aimed at providing new avenues for cancer treatment. Another significant patent involves 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives, which are designed to act as modulators of the CXCR3 receptor, showcasing his focus on developing effective medicaments.

Career Highlights

Throughout his career, Kimmerlin has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Actelion Pharmaceuticals Ltd and Idorsia Pharmaceuticals Ltd. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Kimmerlin has collaborated with several professionals in the field, including Kurt Hilpert and Francis Hubler. These partnerships have likely contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Thierry Kimmerlin's contributions to medicinal chemistry through his patents and collaborations highlight his role as an innovator in the pharmaceutical industry. His work continues to pave the way for new treatments in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…